Teachers Retirement System of The State of Kentucky boosted its position in Insulet Corporation (NASDAQ:PODD – Free Report) by 444.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 173,737 shares of the medical instruments supplier’s stock after buying an additional 141,849 shares during the quarter. Teachers Retirement System of The State of Kentucky’s holdings in Insulet were worth $22,668,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also bought and sold shares of the company. OneDigital Investment Advisors LLC acquired a new stake in shares of Insulet in the second quarter valued at approximately $6,741,000. Headlands Technologies LLC lifted its position in shares of Insulet by 2,041.5% in the second quarter. Headlands Technologies LLC now owns 31,930 shares of the medical instruments supplier’s stock worth $4,861,000 after purchasing an additional 30,439 shares in the last quarter. Amundi lifted its position in shares of Insulet by 13.6% in the second quarter. Amundi now owns 507,847 shares of the medical instruments supplier’s stock worth $77,320,000 after purchasing an additional 60,929 shares in the last quarter. Man Group plc acquired a new position in Insulet during the second quarter worth $78,746,000. Finally, Deutsche Bank AG acquired a new position in Insulet during the second quarter worth $51,153,000.
Wall Street Analyst Weigh In
A number of research analysts recently weighed in on PODD shares. Raymond James Financial reaffirmed an “outperform” rating and issued a $180.00 target price on shares of Insulet in a research report on Thursday, August 6th. BTIG Research cut shares of Insulet from a “buy” rating to a “neutral” rating in a research report on Thursday, August 6th. Citigroup boosted their price target on shares of Insulet from $150.00 to $170.00 and gave the stock a “neutral” rating in a research report on Thursday, November 5th. Wall Street Zen upgraded shares of Insulet from a “hold” rating to a “buy” rating in a research note on Saturday, November 7th. Finally, TD Cowen restated a “hold” rating on shares of Insulet in a report on Wednesday, November 4th. Twelve investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $185.67.
Get Our Latest Stock Report on PODD
Insulet Stock Up 0.0%
NASDAQ:PODD opened at $145.34 on Wednesday. The firm has a market capitalization of $10.08 billion, a price-to-earnings ratio of 23.67, a price-to-earnings-growth ratio of 1.11 and a beta of 1.06. Insulet Corporation has a twelve month low of $126.40 and a twelve month high of $354.88. The stock’s 50 day moving average price is $142.16 and its two-hundred day moving average price is $172.43. The company has a quick ratio of 1.83, a current ratio of 2.51 and a debt-to-equity ratio of 0.60.
Insulet (NASDAQ:PODD – Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.59 by $0.40. The company had revenue of $842.00 million for the quarter, compared to analysts’ expectations of $832.63 million. Insulet had a return on equity of 31.76% and a net margin of 13.44%. The business’s revenue was up 19.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.24 EPS. Equities research analysts expect that Insulet Corporation will post 6.76 earnings per share for the current fiscal year.
Insulet Company Profile
Insulet Corporation is a medical device company focused on insulin delivery for people with diabetes. Founded in 2000, the company developed the Omnipod platform, which delivers insulin through a small, wearable pod without the tubing used by many traditional insulin pumps. Its products include Omnipod DASH and Omnipod 5, an automated insulin delivery system that can adjust insulin delivery based on glucose readings from compatible continuous glucose monitors. Insulet also provides related controllers, mobile app features, supplies and customer support.
Further Reading
- Five stocks we like better than Insulet
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD – Free Report).
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.
